Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

ADAM10 is a principal 'sheddase' of the low-affinity immunoglobulin E receptor CD23.

Weskamp G, Ford JW, Sturgill J, Martin S, Docherty AJ, Swendeman S, Broadway N, Hartmann D, Saftig P, Umland S, Sehara-Fujisawa A, Black RA, Ludwig A, Becherer JD, Conrad DH, Blobel CP.

Nat Immunol. 2006 Dec;7(12):1293-8. Epub 2006 Oct 29.

PMID:
17072319
2.

Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical.

Nisato RE, Hosseini G, Sirrenberg C, Butler GS, Crabbe T, Docherty AJ, Wiesner M, Murphy G, Overall CM, Goodman SL, Pepper MS.

Cancer Res. 2005 Oct 15;65(20):9377-87.

3.

Metalloprotease-disintegrin ADAM8: expression analysis and targeted deletion in mice.

Kelly K, Hutchinson G, Nebenius-Oosthuizen D, Smith AJ, Bartsch JW, Horiuchi K, Rittger A, Manova K, Docherty AJ, Blobel CP.

Dev Dyn. 2005 Jan;232(1):221-31.

4.

Proteases as drug targets.

Docherty AJ, Crabbe T, O'Connell JP, Groom CR.

Biochem Soc Symp. 2003;(70):147-61. Review.

PMID:
14587290
5.
6.

The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion.

Schlomann U, Wildeboer D, Webster A, Antropova O, Zeuschner D, Knight CG, Docherty AJ, Lambert M, Skelton L, Jockusch H, Bartsch JW.

J Biol Chem. 2002 Dec 13;277(50):48210-9. Epub 2002 Oct 7.

7.

The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs.

Amour A, Knight CG, English WR, Webster A, Slocombe PM, Knäuper V, Docherty AJ, Becherer JD, Blobel CP, Murphy G.

FEBS Lett. 2002 Jul 31;524(1-3):154-8.

9.

The role of exon 5 in fibroblast collagenase (MMP-1) substrate specificity and inhibitor selectivity.

Knäuper V, Patterson ML, Gomis-Rüth FX, Smith B, Lyons A, Docherty AJ, Murphy G.

Eur J Biochem. 2001 Mar;268(6):1888-96.

10.

Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1 )integrin, leading to a marked induction of fibroblast cell motility.

Nath D, Slocombe PM, Webster A, Stephens PE, Docherty AJ, Murphy G.

J Cell Sci. 2000 Jun;113 ( Pt 12):2319-28.

11.

The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3.

Amour A, Knight CG, Webster A, Slocombe PM, Stephens PE, Knäuper V, Docherty AJ, Murphy G.

FEBS Lett. 2000 May 19;473(3):275-9.

12.
13.

Inhibition of the metalloproteinase domain of mouse TACE.

Amour A, Hutton M, Knäuper V, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, Docherty AJ, Murphy G.

Ann N Y Acad Sci. 1999 Jun 30;878:728-31. No abstract available.

PMID:
10415820
14.

Matrix metalloproteinase inhibitors block osteoclastic resorption of calvarial bone but not the resorption of long bone.

Everts V, Korper W, Docherty AJ, Beertsen W.

Ann N Y Acad Sci. 1999 Jun 30;878:603-6. No abstract available.

PMID:
10415785
15.

Active gelatinase B is identified by histozymography in the cartilage resorption sites of developing long bones.

Lee ER, Murphy G, El-Alfy M, Davoli MA, Lamplugh L, Docherty AJ, Leblond CP.

Dev Dyn. 1999 Jul;215(3):190-205.

16.

Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone.

Everts V, Korper W, Jansen DC, Steinfort J, Lammerse I, Heera S, Docherty AJ, Beertsen W.

FASEB J. 1999 Jul;13(10):1219-30.

PMID:
10385612
17.

Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity.

Zucker S, Mian N, Drews M, Conner C, Davidson A, Miller F, Birembaut P, Nawrocki B, Docherty AJ, Greenwald RA, Grimson R, Barland P.

J Rheumatol. 1999 Jan;26(1):78-80.

PMID:
9918244
18.

Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells.

Nath D, Slocombe PM, Stephens PE, Warn A, Hutchinson GR, Yamada KM, Docherty AJ, Murphy G.

J Cell Sci. 1999 Feb;112 ( Pt 4):579-87.

19.

TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3.

Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, Stephens PE, Shelley C, Hutton M, Knäuper V, Docherty AJ, Murphy G.

FEBS Lett. 1998 Sep 11;435(1):39-44.

20.

Gelatinase A (MMP-2) and cysteine proteinases are essential for the degradation of collagen in soft connective tissue.

Creemers LB, Jansen ID, Docherty AJ, Reynolds JJ, Beertsen W, Everts V.

Matrix Biol. 1998 Apr;17(1):35-46.

PMID:
9628251
21.

Matrix metalloproteinases and metastatic cancer.

Cockett MI, Murphy G, Birch ML, O'Connell JP, Crabbe T, Millican AT, Hart IR, Docherty AJ.

Biochem Soc Symp. 1998;63:295-313. Review.

PMID:
9513731
22.

Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP).

Zucker S, Drews M, Conner C, Foda HD, DeClerck YA, Langley KE, Bahou WF, Docherty AJ, Cao J.

J Biol Chem. 1998 Jan 9;273(2):1216-22.

24.

Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor.

An Z, Wang X, Willmott N, Chander SK, Tickle S, Docherty AJ, Mountain A, Millican AT, Morphy R, Porter JR, Epemolu RO, Kubota T, Moossa AR, Hoffman RM.

Clin Exp Metastasis. 1997 Mar;15(2):184-95.

PMID:
9062395
25.

A major role for matrix metalloproteinases in T cell injury in the gut.

Pender SL, Tickle SP, Docherty AJ, Howie D, Wathen NC, MacDonald TT.

J Immunol. 1997 Feb 15;158(4):1582-90.

PMID:
9029093
26.
27.

The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function.

Gohlke U, Gomis-Rüth FX, Crabbe T, Murphy G, Docherty AJ, Bode W.

FEBS Lett. 1996 Jan 8;378(2):126-30.

28.

Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer.

Zucker S, Lysik RM, DiMassimo BI, Zarrabi HM, Moll UM, Grimson R, Tickle SP, Docherty AJ.

Cancer. 1995 Aug 15;76(4):700-8.

PMID:
8625169
29.

Binding of gelatinases A and B to type-I collagen and other matrix components.

Allan JA, Docherty AJ, Barker PJ, Huskisson NS, Reynolds JJ, Murphy G.

Biochem J. 1995 Jul 1;309 ( Pt 1):299-306.

30.

Kupffer cell-derived 95-kd type IV collagenase/gelatinase B: characterization and expression in cultured cells.

Winwood PJ, Schuppan D, Iredale JP, Kawser CA, Docherty AJ, Arthur MJ.

Hepatology. 1995 Jul;22(1):304-15.

PMID:
7601425
31.

Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase.

Hill PA, Docherty AJ, Bottomley KM, O'Connell JP, Morphy JR, Reynolds JJ, Meikle MC.

Biochem J. 1995 May 15;308 ( Pt 1):167-75.

32.

An in vivo model for screening peptidomimetic inhibitors of gelatinase A.

Chander SK, Antoniw P, Beeley NR, Boyce B, Crabbe T, Docherty AJ, Leonard J, Mason B, Millar K, Millican AT, et al.

J Pharm Sci. 1995 Apr;84(4):404-9.

PMID:
7629728
33.

Reciprocated matrix metalloproteinase activation: a process performed by interstitial collagenase and progelatinase A.

Crabbe T, O'Connell JP, Smith BJ, Docherty AJ.

Biochemistry. 1994 Dec 6;33(48):14419-25.

PMID:
7981201
34.

Elevated plasma stromelysin levels in arthritis.

Zucker S, Lysik RM, Zarrabi MH, Greenwald RA, Gruber B, Tickle SP, Baker TS, Docherty AJ.

J Rheumatol. 1994 Dec;21(12):2329-33.

PMID:
7699637
35.

The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts.

Hill PA, Murphy G, Docherty AJ, Hembry RM, Millican TA, Reynolds JJ, Meikle MC.

J Cell Sci. 1994 Nov;107 ( Pt 11):3055-64.

36.

Solution structure of the active domain of tissue inhibitor of metalloproteinases-2. A new member of the OB fold protein family.

Williamson RA, Martorell G, Carr MD, Murphy G, Docherty AJ, Freedman RB, Feeney J.

Biochemistry. 1994 Oct 4;33(39):11745-59.

PMID:
7918391
37.

The binding of gelatinases A and B to type I collagen yields both high and low affinity sites.

Allan JA, Docherty AJ, Murphy G.

Ann N Y Acad Sci. 1994 Sep 6;732:365-6. No abstract available.

PMID:
7978809
38.

Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment.

Zucker S, Lysik RM, Zarrabi HM, Moll U, Tickle SP, Stetler-Stevenson W, Baker TS, Docherty AJ.

Ann N Y Acad Sci. 1994 Sep 6;732:248-62. Review. No abstract available.

PMID:
7978797
39.

Mutation of the active site glutamic acid of human gelatinase A: effects on latency, catalysis, and the binding of tissue inhibitor of metalloproteinases-1.

Crabbe T, Zucker S, Cockett MI, Willenbrock F, Tickle S, O'Connell JP, Scothern JM, Murphy G, Docherty AJ.

Biochemistry. 1994 May 31;33(21):6684-90.

PMID:
7911325
40.
41.

Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant.

Murphy G, Nguyen Q, Cockett MI, Atkinson SJ, Allan JA, Knight CG, Willenbrock F, Docherty AJ.

J Biol Chem. 1994 Mar 4;269(9):6632-6.

42.

Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A.

Nguyen Q, Willenbrock F, Cockett MI, O'Shea M, Docherty AJ, Murphy G.

Biochemistry. 1994 Mar 1;33(8):2089-95.

PMID:
8117665
43.

Metalloproteinase domain structure, cellular invasion and metastasis.

Cockett MI, Birch ML, Murphy G, Hart IR, Docherty AJ.

Biochem Soc Trans. 1994 Feb;22(1):55-7. Review. No abstract available.

PMID:
8206283
44.

Recombinant tissue inhibitor of metalloproteinases type 1 suppresses alkali-burn-induced corneal ulceration in rabbits.

Paterson CA, Wells JG, Koklitis PA, Higgs GA, Docherty AJ.

Invest Ophthalmol Vis Sci. 1994 Feb;35(2):677-84.

PMID:
8113019
46.

Crystallization and preliminary X-ray analysis of nonglycosylated tissue inhibitor of metalloproteinases-1, N30QN78Q TIMP-1.

Tolley SP, Davies GJ, O'Shea M, Cockett MI, Docherty AJ, Murphy G.

Proteins. 1993 Dec;17(4):435-7.

PMID:
8108384
47.

The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A.

Willenbrock F, Crabbe T, Slocombe PM, Sutton CW, Docherty AJ, Cockett MI, O'Shea M, Brocklehurst K, Phillips IR, Murphy G.

Biochemistry. 1993 Apr 27;32(16):4330-7.

PMID:
8476862
48.

Site-directed mutations that alter the inhibitory activity of the tissue inhibitor of metalloproteinases-1: importance of the N-terminal region between cysteine 3 and cysteine 13.

O'Shea M, Willenbrock F, Williamson RA, Cockett MI, Freedman RB, Reynolds JJ, Docherty AJ, Murphy G.

Biochemistry. 1992 Oct 27;31(42):10146-52.

PMID:
1420137
49.

Biochemical characterization of matrilysin. Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases.

Crabbe T, Willenbrock F, Eaton D, Hynds P, Carne AF, Murphy G, Docherty AJ.

Biochemistry. 1992 Sep 15;31(36):8500-7.

PMID:
1390635
50.

The matrix metalloproteinases and their inhibitors.

Murphy G, Docherty AJ.

Am J Respir Cell Mol Biol. 1992 Aug;7(2):120-5. Review.

PMID:
1497900

Supplemental Content

Loading ...
Support Center